GLUE
Closed
Monte Rosa Therapeutics Inc
4.61
+0.10 (+2.22%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 4.51
Day's Range: 4.42 - 4.66
Send
sign up or login to leave a comment!
When Written:
8.13
Monte Rosa Therapeutics Inc is a biotechnology company that was founded in 2018. The company is based in South San Francisco, California, and focuses on developing small molecule therapies that target protein-protein interactions (PPIs) to treat cancer and other diseases.
Monte Rosa's technology platform is based on the use of small molecule binders called "molecular glues" that can bind to specific regions of proteins and induce their degradation. This approach has the potential to target previously undruggable proteins and to overcome drug resistance in cancer cells.
The company's lead program is focused on developing a small molecule drug that targets KRAS, a protein that is often mutated in cancer and has been considered a challenging target for drug development. Monte Rosa has also developed a pipeline of other small molecule candidates that target PPIs involved in cancer and other diseases.
Monte Rosa has raised over $95 million in funding from investors, including Versant Ventures, New Enterprise Associates, and GV (formerly Google Ventures). The company is led by CEO Markus Warmuth, who previously served as the Chief Operating Officer of H3 Biomedicine, a cancer drug discovery company.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Monte Rosa's technology platform is based on the use of small molecule binders called "molecular glues" that can bind to specific regions of proteins and induce their degradation. This approach has the potential to target previously undruggable proteins and to overcome drug resistance in cancer cells.
The company's lead program is focused on developing a small molecule drug that targets KRAS, a protein that is often mutated in cancer and has been considered a challenging target for drug development. Monte Rosa has also developed a pipeline of other small molecule candidates that target PPIs involved in cancer and other diseases.
Monte Rosa has raised over $95 million in funding from investors, including Versant Ventures, New Enterprise Associates, and GV (formerly Google Ventures). The company is led by CEO Markus Warmuth, who previously served as the Chief Operating Officer of H3 Biomedicine, a cancer drug discovery company.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!